Search | OpenScholar

Search results

374 results found

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001;57:397-404.

Publication: Journal Article

Group, The Huntington Study. 2001. “A Randomized, Placebo-Controlled Trial of Coenzyme Q10 and Remacemide in Huntington’s Disease. Neurology 2001;57:397-404.”. Neurology.

A home diary to assess functional status in Parkinson’s disease patients with motor fluctuations and dyskinesia. Journal of Clinical Neuropharmacology 2000;23:75-81.

Publication: Journal Article

Hauser, RA, J Friedlander, TA Zesiewicz, CH Adler, LC Seeberger, and . 2000. “A Home Diary to Assess Functional Status in Parkinson’s Disease Patients With Motor Fluctuations and Dyskinesia. Journal of Clinical Neuropharmacology 2000;23:75-81.”. Journal of Clinical Neuropharmacology .

Neural transplantation for the treatment of Huntington's disease. Progress in Brain Research 2000;127:405-11.

Publication: Journal Article

Freeman, TB, RA Hauser, PR Sanberg, and S Saporta. 2000. “Neural Transplantation for the Treatment of Huntington’s Disease. Progress in Brain Research 2000;127:405-11.”. Progress in Brain Research .

Current issues in depression in Parkinson’s disease. Am J Geriatr Psych 1999; :110-118.

Publication: Journal Article

Zesiewicz, TA, M Gold, G Chari, and RA Hauser. 1999. “Current Issues in Depression in Parkinson’s Disease. Am J Geriatr Psych 1999; :110-118.”. Am J Geriatr Psych.

Management of early Parkinson’s disease. Medical Clinics of North America 1999;83:393-414.

Publication: Journal Article

Hauser, RA, and TA Zesiewicz. 1999. “Management of Early Parkinson’s Disease. Medical Clinics of North America 1999;83:393-414.”. Medical Clinics of North America.

Plasma thiamine deficiency associated with Alzheimer’s disease but not Parkinson’s disease. Metabolic Brain Disease 1998;13:43-53.

Publication: Journal Article

Gold, M, R Hauser, and MF Chen. 1998. “Plasma Thiamine Deficiency Associated With Alzheimer’s Disease But Not Parkinson’s Disease. Metabolic Brain Disease 1998;13:43-53.”. Metabolic Brain Disease.

Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology 1998;51:912-913.

Publication: Journal Article

Hauser, RA, AR Malek, and R Rosen. 1998. “Successful Treatment of a Patient With Severe Refractory Myasthenia Gravis Using Mycophenolate Mofetil. Neurology 1998;51:912-913.”. Neurology.

Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998; 55:957-961.

Publication: Journal Article

Kompoliti, K, CG Goetz, BF Boeve, RA Hauser, and . 1998. “Clinical Presentation and Pharmacological Therapy in Corticobasal Degeneration. Arch Neurol 1998; 55:957-961.”. Arch Neurol.

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease: A multicenter 5-year study. Eur Neurol 1997;37:23-27.

Publication: Journal Article

Block, G, C Liss, S Reines, J Irr, D Nibbelink, and CR First Study Group. 1997. “Comparison of Immediate-Release and Controlled Release Carbidopa/Levodopa in Parkinson’s Disease: A Multicenter 5-Year Study. Eur Neurol 1997;37:23-27.”. Eur Neurol.

Effect of lazabamide on the progression of disability in early Parkinson’s disease. Ann Neurol 1996;40:99-107.

Publication: Journal Article

Group, Parkinson Study, and K Kietzburg. 1996. “Effect of Lazabamide on the Progression of Disability in Early Parkinson’s Disease. Ann Neurol 1996;40:99-107.”. Ann Neurol.